Please assess the completion status of the following clinical trial:

Trial Title: Remifentanil in Ventilated Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* preterm infants (\<37weeks of gestational age)~* requiring ventilator care~* informed consent~Exclusion Criteria:~* major anomaly~* 48hrs after birth~* requiring operation during drug infusion~* cord blood pH \< 7.0~* intraventricular hemorrhage grade III or more~* investigators decision

- Gender: ALL
- Minimum Age: None
- Maximum Age: 48 Hours
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 5% dextrose infusion for 72 hours during ventilator care start within 48 hours after birth
- remifentanil (Type: ACTIVE_COMPARATOR): 0.1mcg/kg/min remifentanil infusion for 72 hours during ventilator care start within 48 hours after birth

Based on this trial design, predict the completion outcome and termination type (if applicable).